Nik Chetwyn
About Nik Chetwyn
Nik Chetwyn, Ph.D., is the Chief Operating Officer with a strong background in pharmaceutical chemistry, having held significant roles at major pharmaceutical companies like GlaxoSmithKline, Pfizer, and Genentech.
Nik Chetwyn, Ph.D.: Chief Operating Officer
Nik Chetwyn currently holds the position of Chief Operating Officer. He has extensive experience in the pharmaceutical industry, having worked with prominent companies such as GlaxoSmithKline, Pfizer, and Genentech. At Genentech, he played a key role in building their small molecule drug development organization and expanding their technical and drug manufacturing capabilities.
Educational Background of Nik Chetwyn, Ph.D.
Nik Chetwyn completed his B.Sc. in chemical and pharmaceutical sciences at the University of Sunderland. He further advanced his education by earning an M.S. and Ph.D. in pharmaceutical chemistry from the University of Kansas. This solid educational foundation has equipped him with the knowledge and technical skills necessary for his roles in the pharmaceutical industry.
Industry Experience and Leadership Roles
Throughout his career, Nik Chetwyn has held significant roles in several major pharmaceutical companies. At Genentech, he contributed to the development of the small molecule drug development organization and played a crucial part in the expansion of their technical and drug manufacturing capabilities. He also served on governance committees and was a technical development team leader at Genentech, showcasing his leadership and expertise.
Nik Chetwyn's Governance and Board Representation
Nik Chetwyn has been involved in various governance roles, including serving on multiple governance committees at Genentech. He represented Genentech on the board of directors for the Allotrope Foundation, demonstrating his influence and standing in the pharmaceutical community.
Co-founder of MindScienceConnection, Inc.
Nik Chetwyn co-founded MindScienceConnection, Inc., where he also served as President. This company focuses on strategy and leadership development for biopharmaceutical companies, further highlighting his expertise and commitment to advancing the industry.